KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Receivables (2017 - 2025)

Bionano Genomics' Change in Receivables history spans 7 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Change in Receivables rose 209.45% year-over-year to $1.0 million; the TTM value through Sep 2025 reached -$359000.0, up 89.3%, while the annual FY2024 figure was -$4.1 million, 280.27% down from the prior year.
  • Change in Receivables for Q3 2025 was $1.0 million at Bionano Genomics, up from $141000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.2 million in Q3 2022 and bottomed at -$2.1 million in Q2 2024.
  • The 5-year median for Change in Receivables is $157000.0 (2021), against an average of $35526.3.
  • The largest annual shift saw Change in Receivables surged 611.46% in 2022 before it crashed 347.6% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $157000.0 in 2021, then soared by 611.46% to $1.1 million in 2022, then tumbled by 41.81% to $650000.0 in 2023, then plummeted by 120.46% to -$133000.0 in 2024, then soared by 875.19% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Change in Receivables are $1.0 million (Q3 2025), $141000.0 (Q2 2025), and -$1.4 million (Q1 2025).